About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT01291940

The Effects of Emollient Therapy on the Skin Barrier

The goal of this study is to better understand what effect emollients (moisturizers) have on the skin in young children and adults. Subjects will be recruited from PI and Sub-I clinics and Oregon Hea...

Lead sponsor: Oregon Health and Science University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Oregon Health and Science University

Age

0 - 99 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Pediatric study
•* Enrollment in the BEEP emollient intervention study (IRB #6083)
•* Overall good health
•* Have a history of atopic dermatitis
•* 12 years or older
•* 4 x 4 cm of non-lesional skin on both inner forearms
•* No other conditions that would make the use of the four emollients harmful to the subject, such as known allergy to an emollient or a component o the emollient

Exclusion Criteria

•* Have a history of or are being evaluated for a skin barrier disease
•* Have an active skin infection
•* Are receiving phototherapy
•* Any immunodeficiency disorder or severe genetic skin disorder
•* Any other serious condition that would make the use of emollients inadvisable
•* Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention
•2. Adult Study
•* Use of topical steroids on the inner forearms or oral immunosuppressive medications for 4 weeks prior to participation in the study.
•* Receiving phototherapy or systemic immunosuppressive therapy three months prior to participation in the study.

Related studies

RECRUITINGPhase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697 · Atopic Dermatitis

RECRUITINGPhase 1

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853 · Food Allergy, Loeys-Dietz Syndrome, and more

RECRUITINGPhase 2

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075 · Eczema Atopic Dermatitis, Eczema, and more

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

NCT04455906 · Atopic Dermatitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 15, 2019Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment25

Start dateJan 2011

Last updatedJul 15, 2019

Condition

Atopic Dermatitis Eczema

Locations shown

Oregon Health & Science University Center for Health & Healing

Portland, Oregon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2019Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions